Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
转移性胰腺癌患者每周接受白蛋白结合型紫杉醇联合吉西他滨治疗与单用吉西他滨治疗的随机III期试验（MPACT）中生存预后因素
期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2014-0394
Tabernero, Josep; Chiorean, E Gabriela; Infante, Jeffrey R; Hingorani, Sunil R; Ganju, Vinod; Weekes, Colin; Scheithauer, Werner; Ramanathan, Ramesh K; Goldstein, David; Penenberg, Darryl N; Romano, Alfredo; Ferrara, Stefano; Von Hoff, Daniel D
